Pediatric cancer bill quietly establishes FDA office in Middle East.

What it does

This bill amends federal drug approval rules to require manufacturers of molecularly targeted cancer drugs to conduct pediatric studies before approval, with new enforcement mechanisms and due-process protections. It extends priority review vouchers for rare pediatric disease drugs through 2029, allows the FDA to collect registration fees from organ transplant networks, establishes an FDA office in Abraham Accords countries for regulatory cooperation, increases transparency in generic drug applications, and adds $1.2 billion to the Medicare Improvement Fund.

Why we flagged it

The core mechanism is a legitimate public-health reform (pediatric cancer drug studies and enforcement), but Section 9 (Abraham Accords Office) is a substantively unrelated foreign-policy provision establishing an FDA office in Middle East countries for regulatory cooperation—a rider that has no connection to pediatric cancer or drug safety.

• Establishes FDA office in Abraham Accords countries for regulatory cooperation and technical assistance—unrelated to pediatric cancer drug studies or the bill's stated purpose.

What the text implies

• Organ transplant registration fees (Section 8) create a new revenue stream for OPTN operations but may increase costs for transplant centers and hospitals, potentially reducing transplant access or delaying procedures if fees are passed to patients.
• The Abraham Accords Office (Section 9) represents a significant expansion of FDA's diplomatic footprint in the Middle East (UAE, Bahrain, Morocco, Sudan) without explicit authorization for the cost or staffing model, and the 3-year sunset on OPTN fees suggests the bill's financing is temporary.
• Pediatric study requirements apply only to applications submitted 3 years after enactment (2028+), creating a 3-year lag before the rule takes effect and allowing manufacturers to file applications before the new requirements apply.
• Generic drug transparency provisions (Section 10) require FDA to disclose whether generics match brand-name drugs in inactive ingredients, but explicitly preserve trade-secret protections for brand-name formulations—a partial transparency measure that may not fully level the playing field.
• The bill's title honors Mikaela Naylon (a deceased child with cancer) but the substantive pediatric cancer provisions are narrow (molecularly targeted drugs only) and do not address broader pediatric cancer drug access or affordability.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Pediatric cancer drug studies and transparency in generic applications benefit patients by ensuring safer, tested pediatric formulations and clearer drug equivalence. However, the Abraham Accords Office is a geopolitical rider unrelated to pediatric health, and the organ transplant registration fee creates a new cost on transplant networks that may be passed to patients or reduce transplant access. The net effect on ordinary citizens is unclear.

Who stands to gain

• pharmaceutical manufacturers (pediatric study credit incentives, priority review vouchers)
• organ procurement organizations (registration fee revenue)
• FDA (expanded budget and international presence)

Named in the bill

FDA (Food and Drug Administration), HHS (Department of Health and Human Services), OPTN (Organ Procurement and Transplantation Network), Abraham Accords countries (UAE, Bahrain, Morocco, Sudan), pharmaceutical manufacturers, generic drug manufacturers, organ transplant centers, Section 505B (pediatric study requirements), Section 529 (priority review vouchers), Section 527 (orphan drug exclusivity)

Where it stands

313 cosponsors: 180 Democrats, 132 Republicans, 1 Independents.

• Feb 12, 2025 — Introduced · Congress.gov: “Introduced in House”
• Feb 12, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
• Sep 17, 2025 — Markup held in committee · Congress.gov: “Committee Consideration and Mark-up Session Held”
• Sep 17, 2025 — Reported out of committee · Congress.gov: “Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 47 - 0”
• Dec 1, 2025 — Passed the House · Congress.gov: “On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4929-4932)”
• Dec 1, 2025 — Floor vote scheduled · Congress.gov: “Mr. Carter (GA) moved to suspend the rules and pass the bill, as amended”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

45 lobbying clients named this bill on 60 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $26,932,605 in lobbying spend. A filing names 7 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 99% of bills with at least one filing.

Michael McCaul, the sponsor, reported $80,800 in PAC receipts in the 2026 cycle.

• Pharmaceutical Research and Manufacturers of America — $15,770,000 on 2 filings
• Novartis — $1,410,000 on 1 filing
• National Association of Children's Hospitals (n.a.c.h.) — $1,370,000 on 1 filing
• Acadia Pharmaceuticals — $1,290,000 on 2 filings
• Biogen — $1,060,000 on 1 filing

Lobbying Disclosure Act filings through Jul 22, 2026. A filing shows who paid to lobby on a bill it names, not what changed.